TG Therapeutics is focused on developing & delivering medicines for patients with B-cell malignancies. TG has 5 drug candidates in development with ublituximab & umbralisib in pivotal trials for CLL, NHL and MS. Ublituximab is a novel glycoengineered anti-CD20 mAb & umbralisib is an oral, QD, PI3K-delta inhibitor with unique inhibition of CK1-epsilon. In Phase 1 development TG also has an anti-PD-L1 mAb (TG-1501), an oral BTK inhibitor (TG-1701) & an anti-CD47/CD19 bispecific antibody (TG-1801).